REGN is up 0.33% today. Volume is 418.1K vs a 30-day average of 731.6K (0.57x).
Regeneron Pharmaceuticals, Inc. is scheduled to report earnings Fri, Oct 30, 2026 · before open. Analysts expect EPS of $16.48 on revenue of about $4.63B. Stocks often move sharply on earnings day.
Regeneron (NASDAQ:REGN) reports third-quarter results on Oct. 30. Regeneron books its full share of Dupixent profits from Sanofi (NASDAQ:SNY) for the first time this quarter. I th…
Updated agreement expands 2020 procurement agreement with BARDA for Regeneron's first-in-class antibody treatment for Orthoebolavirus zairense, adding value of approximately $270 …
Regeneron (REGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
TD Cowen analyst Tyler Van Buren maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and raises the price target from $960 to $980.
Longleaf Partners, managed by Southeastern Asset Management, released its third-quarter 2026 investor letter for its “Partners Fund”. The letter can be downloaded here. Coming int…